DOP003: Cromoendoscopy versus second generation Narrow band Imaging for dysplasia detection in IBD. A prospective randomized controlled trial.ECCO'25 Berlin
2025
DOP004: Proactive fecal calprotectin testing in ulcerative colitis: Initial results of the PROMOTE UC studyECCO'25 Berlin
2025
DOP005: Long-term efficacy and safety of mirikizumab treatment for Crohn’s Disease: Results from the VIVID-2 open-label extension studyECCO'25 Berlin
2025
DOP006: Long term maintenance treatment with vedolizumab in pediatric IBD: a three-year follow-up of the prospective multicenter VEDOKIDS studyECCO'25 Berlin
2025
DOP007: Change in Histological inflammation in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trialECCO'25 Berlin
2025
DOP010: Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics–pharmacodynamics studyECCO'25 Berlin
2025
DOP011: Colectomy rates of newly diagnosed Finnish Ulcerative Colitis patients are decreasingECCO'25 Berlin
2025
DOP012: Promising effects of IMU-856, an orally available epigenetic modulator of barrier regeneration - biomarker findings from a Phase 1 clinical studyECCO'25 Berlin
2025
DOP013: Risk of immune mediated inflammatory diseases associated with anti-TNFs and ustekinumab in Crohn’s disease: a nationwide population-based cohort studyECCO'25 Berlin
2025
DOP015: Consistency and Quality of Inflammatory Bowel Disease care in Australasia; Towards Benchmarking, Crohn’s Colitis Cure Data Insight’s Program.ECCO'25 Berlin
2025
DOP017: Infliximab induction fails to reach targets in Perianal Fistulizing Crohn’s Disease: first results from the ATLANTIC studyECCO'25 Berlin
2025
DOP018: Etrasimod for the treatment of Ulcerative Colitis: Up to 4 years of safety data from the global clinical programmeECCO'25 Berlin
2025